NCT07170306Not yet recruiting
Cardiac Amyloidosis in Patients With Aortic Stenosis
A Study on the Prevalence and Clinical Characteristics of Cardiac Amyloidosis in Patients With Aortic Stenosis
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
This study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS), compare the clinical characteristics between patients with isolated AS and those with AS complicated by CA (CA-AS), and simultaneously explore the impact of transcatheter aortic valve replacement (TAVR) on serum transthyretin (TTR) levels in patients with AS complicated by transthyretin amyloidosis (ATTR-AS), as well as its influence on the treatment outcomes of patients with isolated AS and ATTR-AS.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 143 (estimated)
- First submitted
- 5 Sept 2025
- Start date
- 31 Jan 2026
- Primary completion date
- 31 May 2028
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Amyloidosis
- NCT number
- NCT07170306
What you commit to
- Study type: Observational
- Planned participants: 143
- From 31 Jan 2026 to the primary completion date, 31 May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other ongoing investigational studies of drugs or medical devices that have not yet been completed;
Other illness
- Aortic stenosis (AS) caused by congenital diseases or rheumatic immune diseases;
- Severe renal impairment, chronic dialysis, or unresolved acute kidney injury after transcatheter aortic valve replacement (TAVR);
- Terminal-stage diseases with an expected life span of \< 6 months;
- Failure to undergo TAVR surgery, transfer to surgical treatment, or in-hospital death.
Other
- Patients who are unable to attend the follow-up visits scheduled in the study;
Who the study is looking for
- Male or female patients aged ≥ 65 years and ≤ 85 years;
- Patients with moderate-to-severe degenerative aortic stenosis (AS) who are hospitalized and scheduled to undergo transcatheter aortic valve replacement (TAVR);
- Patients who voluntarily sign the Informed Consent Form (ICF) and are able to comply with the study-specified treatment plan, follow-up visits, laboratory tests, and other requirements.
Age in the registry: 65 years to 85 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.